Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines PipelineBenzinga • 09/30/24
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis PotentialBenzinga • 09/27/24
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)Seeking Alpha • 09/27/24
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World SettingBusiness Wire • 09/27/24
Bristol Myers Squibb shares move higher on FDA approval of schizophrenia drugProactive Investors • 09/27/24
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 DecadesBenzinga • 09/27/24
Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline ProgressSeeking Alpha • 09/27/24
Bristol Myers Stock Jumps. Why Approval for Its Schizophrenia Drug Is Ground Breaking.Barrons • 09/27/24
US drug regulator approves the first new schizophrenia drug in 30 yearsProactive Investors • 09/27/24
U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in AdultsBusiness Wire • 09/27/24
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals BreakoutInvestors Business Daily • 09/26/24
FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decadesCNBC • 09/26/24
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To ProfitabilityBenzinga • 09/25/24
